©2021-2032
All Rights Reserved. Online Journal of Veterinary Research . You may not store
these pages in any form except for your own personal use. All other usage or
distribution is illegal under international copyright treaties. Permission to
use any of these pages in any other way besides the
before mentioned must be gained in writing from the publisher. This
article is exclusively copyrighted in its entirety to OJB publications. This
article may be copied once but may not be, reproduced or
re-transmitted without the express permission of the editors. This journal satisfies the
refereeing requirements (DEST) for the Higher Education Research Data
Collection (Australia). Linking:To link to this page or any pages linking to this page
you must link directly to this page only here rather than put up your own page.
OJVRTM
Online Journal of Veterinary
Research©
Effect of Remdesivir
and Chloroquine on hypertensive ACE drugs in COVID 19 patients.
Tayseer Shaker Mahmood
Department
of Nursing, Al-Hadi University College, Baghdad, Iraq
ABSTRACT
Mahmood TS., Effect
of Remdesivir and Chloroquine on hypertensive ACE drugs
in COVID 19 patients, Onl J Vet Res., 25 (5): 350-353,
2021. Coronaviruses of single sense strand
RNA genome are enveloped viruses infecting humans and animals responsible for severe
acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and SARS-CoV2
COVID-19 responsible for worldwide pandemic with ~2M deaths to date. To manage
hypertension, patients are given angiotensin converting enzyme receptor
blockers (ACE) but there is scant information of possible interaction with COVID
19 treatments. Potential therapies for COVID 19 before severe symptoms are
manifested include hydroxychloroquine, chloroquine phosphate, remdemsivir, ivermectin and lopinavir/ritonavir with or without zinc. Hypertensive COVID 19 patients using ACE
receptor inhibitors are at increased risk by enhancing ACE2 blockers in
epithelial cells lining the lung, where SARS-CoV-2is more likely to infect
these cells via ACE2 receptors. Similarly, ACEI and ARBs drugs are shown to
interact with several antiretroviral drugs leading to increase viral load. Chloroquine
has an antagonistic effect with remdesivir which
leads to decrease therapeutic activity of remdesivir.
These results highlight possible risk of combination therapies with ACEI and ACE2.
Keyword: COVID-19, SARS, Remdesivir,
Chloroquine, Antagonism, ACEI.
FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE